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Abstract: HyBeacons are linear oligonucleotides which incorporate fluorescent dyes covalently 16 
linked to internal nucleotides. They have previously been used with PCR and isothermal 17 
amplification to interrogate SNPs and STRs in fields as diverse as clinical diagnostics, food 18 
authentication, and forensic DNA profiling. This work explores their use for the identification of 19 
expressed gene sequences through mRNA profiling. The use of mRNA is becoming increasingly 20 
common in forensic casework to identify body fluids on evidence items, as it offers higher specificity 21 
and fewer false positives than current chemical presumptive testing methods. The work presented 22 
here details the development of a single-step one-tube RT-PCR assay to detect the presence of body 23 
fluids of forensic interest (saliva, blood, seminal fluid, vaginal fluid and menstrual blood) using 24 
HyBeacon® probes and melt curve analysis. Each assay shows a high degree of specificity to the 25 
target body fluid mRNA suggesting there is no requirement to remove genomic DNA prior to 26 
analysis. Of the five assays developed, four were able to detect between 10 and 100 copies of target 27 
cDNA, the fifth 1000 copies of target. The results presented here demonstrate that such an approach 28 
can be optimised for non-expert users and further areas of work are discussed.  29 
 30 
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 33 
Introduction 34 
Recent research has shown that HyBeacon probes offer a flexible and robust approach to nucleotide 35 
sequence detection across a variety of applications [1-8]. The versatility of the probe comes from the 36 
design which is specific to a complimentary target sequence. When hybridised to single-stranded 37 
target DNA they emit greater amounts of fluorescence than when un-bound. Detection is performed 38 
using melt curve analysis, and the temperature at which the probe dissociates from the target is 39 
determined by the degree of complementarity between the probe and the sequence to which is it 40 
bound, and can easily span a range of 30°C for the detection of mismatched or partially 41 
complementary target sequences [4,5]. This DNA based approach has allowed scientists to compare 42 
and match samples in a large number of applications ranging from Single Nucleotide Polymorphism 43 
(SNP) analysis (Figure 1A) in food and medical diagnostic applications [7,8] to Short Tandem Repeat 44 
(STR) profiling (Figure 1B) in the analysis of forensic samples [4,5]. However, the detection of 45 
expressed gene products such as mRNA sequences, rather than DNA, is becoming increasingly 46 
important in a variety of fields. Research looking to measure and detect mRNA expression patterns 47 
in tissues often have a health focus such as disease diagnostics [9,10], susceptibility [11] and 48 
treatment [12], although there are other non-health applications which have no need to identify 49 
gene mutations or expression level and are simply concerned with the provenance of a biological 50 
sample.  51 
Body Fluid Identification (BFID) forms part of the field of forensic genetics [14]. Investigations can 52 
often require activity level or cell source information which can allow the linking of a downstream 53 
DNA profile to a body fluid (and therefore an individual or action), or to allow discrimination 54 
between two versions of an event [13, 14]. Currently this information is mainly acquired using 55 
chemical tests (such as the Kastle-Meyer test for blood [15]) or microscopy (in the case of the 56 
identification of sperm [15]) to identify a body fluid. However, these tests can be time consuming, 57 
require expert interpretation, use hazardous chemicals, and are subject to a number of false 58 
positives. In addition such tests are generally not human-specific, although antibody based tests that 59 
have fewer false positives do exist for some sample types [16,17]. Research in this field has seen a 60 
steady progression towards assessing and understanding the utility of messenger RNA (mRNA), DNA 61 
methylation profiling [18-20], micro RNA (miRNA) [21-23] and microbial markers [14] to confirm the 62 
presence of forensically relevant body fluids on evidence items, such as swabs from sexual assault 63 
kits [14]. Today mRNA detection is an extensively researched method and a number of mRNA 64 
markers for forensically-relevant body fluids, such as saliva, seminal fluid, blood, menstrual blood 65 
and cervicovaginal fluid (CVF) have been identified [24-30]. A selection of these identified mRNA 66 
markers has been tested through European DNA Profiling Group (EDNAP) exercises [31-35]. 67 
Increasingly, forensic laboratories are beginning to offer mRNA profiling as a routine part of 68 
casework services [36, 37]. While these developments address the specificity and sensitivity issues of 69 
simpler detection methods, new issues arise out of the more complex lab procedures required to 70 
isolate mRNA and remove any contaminating genomic DNA (gDNA), generate complementary DNA 71 
(cDNA) through Reverse Transcription (RT), amplify the resulting cDNA, and then differentiate the 72 
fragments, usually accomplished by capillary electrophoresis (CE) or high resolution melting 73 
(HRM)[38].  74 
The specificity of a HyBeacon probe to its complementary sequence and its detection using melt 75 
curve analysis may solve many of the processing issues currently encountered by laboratories 76 
performing this service, and also serve to demonstrate the wider applicability of HyBeacon detection 77 
to mRNA. Positioning the probe such that it spans an exon:exon junction in mature mRNA (see Fig 78 
1c) will allow differentiation between gDNA and mRNA. Where the intron is present in the gDNA, the 79 
probe will hybridise to a reduced number of nucleotides, resulting in a melt peak with a lower 80 
melting temperature (Tm) than one where the probe is fully hybridised to the target sequence. This 81 
allows the specific detection of mRNA targets in a sample where the gDNA is still present. The 82 
development of a one step approach to RT-PCR followed by melt curve detection, without further 83 
sample manipulation, further simplifies this process, increasing the usability for non-specialists.  84 
The aim of this work was to develop a one-step RT-PCR process that would allow for the 85 
identification of body fluids from RNA extracted samples with gDNA still present, and that could be 86 
performed on a standard PCR and fluorescence detection platform. The single-step process would 87 
reduce the cost and time required for a result and would also allow for the RT and PCR steps to 88 
occur in a single tube, reducing the complexity of the process. The eventual scope of this work is to 89 
develop a simple system where a user can directly sample from a crime stain of interest and identify 90 
the body fluid present without any further manipulation of the sample or extract, similar to the 91 
generation of a DNA profile directly from evidence items using the ParaDNA Intelligence Test [4]. 92 
Here we present data on the initial assessment of the utility of HyBeacon probes for use in mRNA 93 
gene expression detection using the forensically relevant system of body fluid identification. 94 
 95 
Materials and methods 96 
Samples used in study 97 
Swabs of relevant body fluids were donated by volunteers after full informed consent was obtained 98 
following procedures approved by ethics review board. Vaginal and menstrual material was 99 
collected on low vaginal swabs using Bode SecurSwabs (Cat no: P08D72, Bode Technology, VA, USA). 100 
Blood, saliva and ejaculate were collected onto cotton-tipped swabs (Cat no: 11502483, Fisher, UK). 101 
All donations were anonymised at the point of collection by the donors and stored at -20°C until 102 
required. Total RNA was extracted from swabs using QIAamp RNA Blood Mini Kit (Cat no: 52304, 103 
Qiagen, Manchester, UK) following the manufacturers recommended conditions. Extracts were 104 
treated with DNase folloǁiŶg ŵaŶufaĐturer’s iŶstruĐtioŶs during extraction to remove 105 
contaminating gDNA (RNase-free DNase set Cat no: 79254, Qiagen, Manchester, UK). Extracts were 106 
eluted in 50 µl of RNase-free water and stored at -20°C until needed. Total RNA concentration for 107 
extracts was determined using a NanoDrop® ND-1000 (ThermoScientific, UK). Several of the body 108 
fluids tested in this work include those with a high microbial load (saliva, cervicovaginal fluid, 109 
menstrual blood), so any co-purified microbial RNA will contribute to the total RNA concentration 110 
determined. Panels of purified DNA from human lymphoblast transformed cell lines were used as 111 
the gDNA source (Public Health England, Salisbury, UK). The gDNA samples were RNase treated 112 
folloǁiŶg ŵaŶufaĐturer’s iŶstruĐtioŶs to ensure any non-specific amplification observed using the 113 
HyBeacon probe could be identified as gDNA (RNase A Cat no: 19101, Qiagen, Manchester, UK).  114 
 115 
Primer and HyBeacon® probe design: 116 
Multiple primer sets were designed for each of the target mRNAs using AmplifX 1.7.0 software [39]. 117 
In silico specificity checks were performed using Primer-BLAST [40]. Primers were designed to flank 118 
an exon:exon junction and were supplied by Eurofins (Eurofins MWG Synthesis GmbH, Germany). 119 
Once optimal primer pairs had been selected, HyBeacon probes (Table 1) were designed and labelled 120 
with two fluorescein (FAM) dT monomers (Glen Research, Virginia, USA). Probes were supplied by 121 
LGC Biosearch Technologies, CA, USA. All oligonucleotides were supplied lyophilised, and were 122 
reconstituted in low-EDTA TE (IDT, Leuven, Belgium) and quantified using a NanoDrop® ND-1000. 123 
 124 
Characterisation studies 125 
RT-PCR was performed using a CFX96 Real-Time Detection System (Bio-Rad Laboratories) in 126 
Framestar® 96 well low-profile non-skirted qPCR plates sealed with optically clear caps (Cat nos: 4ti-127 
0721 and 4ti-0751, 4titude, Surrey, UK). Qiagen OneStep RT-PCR kits (Cat no: 210212, Qiagen, 128 
MaŶĐhester, UKͿ ǁere set up aĐĐordiŶg to ŵaŶufaĐturer’s specifications, with asymmetric primer 129 
concentrations of 1 μM excess primer, 0.25 μM limiting primer and 0.3μM HyBeacon probe, and 130 
final reaction volume of 20µl. Sample volumes were two µL per well. Total input amounts of the 131 
different targets are detailed below. The RT-PCR conditions for this study were as follows: 50°C for 132 
30 minutes, 95°C for 15 minutes, PCR cycling 94°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec, with a 133 
plate read at 54°C for 10 sec every cycle for real-time PCR when required by experimental design for 134 
assay evaluation (total cycle number = 50). Melting curve analysis was performed immediately after 135 
RT-PCR using a hold at 72°C for 10 minutes, cool to 30°C at 0.1°C/sec, melt 30°C to 80°C at 0.5°C/sec 136 
including a plate read.   137 
The specificity of the assay to its target body fluid was assessed by performing triplicate RT-PCR 138 
amplification of mRNA extract from all other body fluids considered as part of this work, as well as 139 
extracted gDNA. Where the extract concentration was above 10ng/µl (CVF and menstrual extracts 140 
only), samples were diluted to this concentration with DEPC-treated water (Cat. No: 95284, Sigma) 141 
before being added to reactions. Sample volume of two µl was added to the reactions, so the 142 
amount of total RNA being added to a reaction varied between 20ng and 0.8ng. The mRNA target 143 
would make up only a small proportion of this amount. 144 
The sensitivity of the assay to its target body fluid was assessed by amplification of serial dilutions of 145 
plasmids of a known copy number, each containing a cDNA gene sequence fragment for an mRNA 146 
target. Plasmid construction for each target was outsourced (GenScript USA Inc, NJ, USA) whereby a 147 
310-350bp cDNA gene sequence fragment was inserted into pBluescript II SK(+) . The sequence 148 
fragment for each target included the entire length of the target amplicon, including primer sites, so 149 
that the same reaction mix set-up could be used for plasmid work as for all other input template 150 
types. Plasmids were resolvated with DEPC-treated water (Sigma-Aldrich, Poole, UK) to a standard 151 
stock concentration iŶ Đopies/µL, ĐalĐulated froŵ the ŵaŶufaĐturer’s stated yield iŶ Ŷg aŶd the 152 
molecular weight of the plasmid. The use of a known number of copies of plasmid added to the 153 
reaction allowed an estimate of the total number of cDNA copies transcribed after RT-PCR to be 154 
determined (noted in Table 2) – this assumes 100% RT-PCR efficiency.  155 
Variation between donors was assessed by extracting total RNA from multiple doŶors’ target body 156 
fluid swabs (peripheral blood – 8 donors; saliva – 5 donors; seminal fluid – 7 donors; menstrual 157 
blood - 4 donors; cervicovaginal fluid – 5 donors). Total RNA from each extract was quantified and 158 
where the concentration exceeded 10ng/µl (CVF and menstrual swabs only), extracts were diluted to 159 
10ng/µl using DEPC-treated water. For each body fluid assay, 2µl samples of the extracted target 160 
body fluid swab from each donor were amplified in duplicate. The peripheral blood marker (ALAS2) 161 
was tested with both peripheral blood and menstrual blood extracts as one donor was only 162 
represented by a menstrual sample. The vaginal secretions marker (CYP2B7P1) was likewise tested 163 
with both vaginal and menstrual extracts as it was expected to be present in both, and one donor 164 
was only represented by a menstrual swab sample.  165 
 166 
SNP Screening  167 
To identify and assess the impact of SNPs for each of the five mRNA markers, putative SNP sites 168 
were identified within the probe binding sites within each gene. This was done in two ways; firstly, 169 
the GenBank database was searched for currently identified genetic variations within each marker; 170 
secondly, 24 gDNA samples underwent DNA sequencing across the regions of interest. PCR product 171 
was generated using AmpliTaq Gold 360 DNA Polymerase (Cat no: 4398823, Applied Biosystems) at 172 
1x, 25 µL reaction volume, 2.5mM MgCl2, final primer concentrations of 0.5µM. The optimised PCR 173 
protocol was run on a CFX96 as follows: 95°C for 10 minutes, PCR cycling conditions 95°C/30 sec, 55-174 
65°C/30 sec, 72°C/1 minute, total of 35 cycles. Final hold at 72°C for 7 mins. The resulting PCR 175 
product underwent ExoSAP clean up (Affymetrix, High Wycombe, UK), and was amplified using 176 
BigDye® Terminator v3.1 Cycle Sequencing Kit (LifeTechnologies) using the LabCycler (SensoQuest). 177 
CE was performed on an ABI 3730xl DNA Analyzer XL (LifeTechnologies) using polymer pop7 by LGC 178 
Genomics (Berlin, Germany). Sequence Data was examined using Chromas Lite 2.1.1 (Technelysium 179 
Pty Ltd).  180 
If SNPs were identified under HyBeacon probe binding sites, reverse compliment (RC) oligos for the 181 
probe sequences were synthesised that included one of the identified SNPs (Eurofins MWG 182 
Synthesis GmbH, Germany). These were then added to enzyme-free reactions with the probe for the 183 
marker of interest and melting curve analysis was performed. Six replicate tests were performed for 184 
each RC target and any differences in peak Tm or height were noted and statistically examined for 185 
significance using Mann-Whitney U tests and StudeŶt’s t-tests. While the conditions of the melt 186 
reaction did not precisely mimic the optimised RT-PCR conditions they provide an approximate 187 
assessment of the likely impact a genetic variation has on melt peak temperature. 188 
 189 
Results and Discussion 190 
HyBeacon Assay Designs 191 
Previous research has identified a number of mRNA markers specific to body fluids of forensic 192 
relevance (summarised in Table 1).  After an initial screen of primer candidates based on real-time 193 
PCR quantification cycle (Cq) values and final melt peak appearance (data not shown), the primer 194 
combinations were reduced to a single forward and reverse primer (Table 1). After primers were 195 
selected, HyBeacon probes were designed for each of the markers to anneal across exon:exon 196 
junction regions. This enabled a design with 100% homology between the HyBeacon probe and 197 
mRNA strands with reduced homology between the HyBeacon and gDNA strand containing the 198 
intron (as shown in Figure 1c). It was expected that this reduced homology would cause a reduction 199 
in the melt temperature of peaks associated with gDNA, thereby providing a categorical 200 
differentiation between target mRNA and secondary gDNA. A first requirement of the HyBeacon 201 
assay design was that the melt curve generated from any target sample mRNA input was clearly 202 
differentiated from any melt curves generated from any co-amplified gDNA product. In addition, the 203 
gDNA fragment is expected to be larger than the target mRNA, due to the inclusion of the intron, 204 
leading to a preferential amplification of the smaller mRNA target. In all tests amplification of the 205 
target and the presence of a melting peak at the expected Tm (60°C for all markers) was seen in all 206 
positive control samples (extracted RNA and cDNA). In addition, the gDNA fragment would be larger 207 
than the target mRNA, due to the inclusion of the intron, potentially leading to preferential 208 
amplification of the smaller mRNA target. A small, lower Tm gDNA peak was identified in ALAS2, 209 
SEMG1, MMP10 and CYP2B7P1 assays (Figure 2, Table 2).  210 
No gDNA peak was produced in the HTN3 assay. This is likely because the structure of the HTN3 211 
mRNA allowed both primers as well as the probe to lie over at least one exon:exon junction each 212 
(one of which exceeds 2000bp), which strongly discourages the amplification of gDNA during PCR.  213 
 214 
Characterisation studies 215 
The second requirement of the HyBeacon assay was for the markers to be specific to the body fluid 216 
in question. SEMG1, HTN3 and MMP10 peaks were only seen from the expected body fluid mRNA 217 
template (Table 1). Peaks were seen in ALAS2 reactions for both peripheral and menstrual blood 218 
mRNA (Figure 3), which is expected as peripheral blood is a component of menstrual blood. Peaks in 219 
CYP2B7P1 reactions were also seen from menstrual mRNA, which again is expected as vaginal 220 
material is present in menstrual blood. For both of these markers, purified mRNA from menstrual 221 
blood was a better source of template (based on the lower mean Cq values seen) than purified 222 
mRNA from either peripheral blood (for ALAS2 mean Cq 35.0 for peripheral blood, 33.6 for 223 
menstrual) or vaginal fluid (for CYP2B7P1 mean Ct 41.42 for vaginal secretions, 31.33 for menstrual). 224 
As all template types for one assay were run on the same plate, this is probably indicative of 225 
differences in expression levels of different mRNA species between donors and tissues, or an 226 
indication of the quality of purified mRNA that can be obtained from these sources. No peaks were 227 
observed in either assay from the remaining body fluid types tested. 228 
Forensic samples can be small in size or low in template, so it is important that any assay developed 229 
is able to provide a result with a small amount of input template. The performance of the assays 230 
developed in this work will be dependent on a number of factors: the efficiency of the assay itself, 231 
differences in expression of the target marker in the sample being tested (which can vary between 232 
donors, and within the same donor over time), and (particularly if crude sample analysis is required), 233 
the presence of inhibitors. Primer and probe sets were initially tested for sensitivity using serial 234 
dilution of plasmid targets to remove the impact of differences in amount of target present between 235 
total mRNA extracts from samples of the same body fluid. All assays were run in duplicate against 236 
10-fold dilutions from 100,000 copies/well to 1 copy/well. The limit of detection (LoD) was defined 237 
as the input amount that gave discernible peaks (by eye) in both replicate samples (LoD ALAS2 = 10 238 
copies, MMP10 = 10 copies, CYP2B7P1 = 1000 copies, HTN3 = 100 copies, SEMG1 = 10 copies). It is 239 
unclear why the CYP2B7P1 assay has a significantly higher LoD than the other assays, but it is 240 
thought this is related to lower primer efficiency which forms part of an ongoing study.    241 
 242 
Variations between donors 243 
It was necessary to determine if differences in gene sequences between donors (e.g. SNPs, or splice 244 
variants) would lead to differences in melt peak Tms or assay performance. Expression of the markers 245 
of interest was likely to vary between donors, and within the same donor over time (e.g. expression 246 
of MMP10 during menstrual cycle).  247 
There was a maximum of 3°C difference between melt peak Tms across all donors tested within each 248 
assay (Table 2), and the spread of Tms was only marginally greater than the differences seen in Tm 249 
between repeats from the same donor and was not statistically significant, suggesting that 250 
instrument variation played more of a role in peak Tm than donor-to-donor variation. All extracts 251 
tested against the marker panel gave the expected results. This suggests that, within this fairly 252 
limited donor pool, there were no SNPs or splice variants within the probe annealing regions, and no 253 
donors who did not express the target mRNA at sufficient levels for detection.  254 
qPCR Cq values for samples varied between donors, but were consistent between repeats from the 255 
same donor extract (Table 2). CYP2B7P1 had the widest spread of Cq values across all of the samples 256 
tested possibly due to poor amplification of one of the vaginal samples. Further work is required to 257 
determine if this variation in performance is due to varying expression levels of CYP2B7P1 during the 258 
menstrual cycle, or sample degradation after collection. 259 
 260 
SNP Screening 261 
HyBeacon® melt analysis relies on complementarity between the probe and the target sequence. 262 
Most of the markers chosen for this work are based on genes which are expressed into functional 263 
proteins.  The exception is the CYP2B7P1 marker, which is classed as a pseudogene as, although 264 
mRNA is transcribed from the genome, it is not further translated into protein [30]. Many of these 265 
mRNA species are believed to be functional, although the function, if any, of the CYP2B7P1 mRNA 266 
has yet to be determined [30].  Given the highly conserved nature of such coding regions it was 267 
expected that the number of SNPs observed in the screening study would be low. A sample screen 268 
would identity any SNPs within probe target sequences that would lead to changes in peak 269 
temperature, which would complicate the use of automated software to determine the presence or 270 
absence of the marker of interest based on melt peak Tms. Another reason to screen for SNPs was 271 
the possibility that there may be disease traits linked to the variations in the gene sequences. For 272 
the purposes of the body fluid detection approach it would be important to avoid the release of 273 
sensitive health information during the analyses of a crime scene sample.  274 
GenBank data was interrogated to determine if reported SNPs existed within probe sites. Details of 275 
the numbers of SNPs identified for each marker and within each probe region are given in Table 3. 276 
None of the SNPs identified in the GenBank data were associated with disease states at the time of 277 
analysis. More than one SNP variant was identified at one locus under the HTN3 probe; this is 278 
highlighted in Table 3. There was no suggestion in the GenBank data of linkages between the SNPs of 279 
interest to our analysis, although there was no frequency data associated with any of the SNPs 280 
identified in the GenBank data. Data from the variation between donors study above suggested that 281 
none of the individuals tested possessed SNPs within the probe sites that affected probe Tm, as there 282 
was little variation in the melt peak Tms. However, this pool of donors was relatively small and non-283 
diverse, so sequencing of commercially available gDNA samples from 24 individuals from more 284 
ancestrally diverse populations was undertaken. Samples were taken from the panels of purified 285 
human lymphoblast transformed cell lines provided by Public Health England (Salisbury, UK). 286 
Samples were taken as follows: 10 random individuals from the UK Caucasian donors on the Human 287 
Random Control DNA Panel HRC-5, two donors from each of the following ethnic groups from the 288 
Ethnic Diversity DNA Panel EDP-1; Japanese, Aborigine Australian, Thai, Oriental, Black African, 289 
Ashkenazi Jew and South American Indian. Populations were defined by the supplier of the DNA 290 
panels. This approach was practically easier than generating data directly from mRNA collected from 291 
multiple individuals given the personal nature of the samples and the scope of populations offered 292 
by using the EDP-1 panel. Where multiple introns occurred in the gDNA, a number of flanking primer 293 
sets were designed to amplify each region, with junctions identified and matched together 294 
afterwards. None of the samples sequenced contained any SNPs under probe binding sites (data not 295 
shown).  296 
In order to determine the impact of the presence of any SNPs within the probe binding sites, RC 297 
oligos were generated as detailed in Table 3, and probes were melted with these RC templates. Melt 298 
curve data resulting from analyses of probes with RC sequences showed that in all instances the wild 299 
type RC/probe combination had the highest peak Tm (Table 4). Subsequent statistical analysis of the 300 
wild type and non-wild type peak Tms (Mann-Whitney U test) and peak height (student t-test) 301 
indicated that the presence of a SNP within the probe annealing region led to a statistically 302 
significant decrease in melt peak Tm in all instances (p≤ 0.05). The maximum difference seen was a 303 
decrease of 7.1°C (CYP2B7P1 RC1). The CYP2B7P1 polymorphisms observed are located towards the 304 
centre of the probe, and are therefore more destabilising. RC1 is the most destabilising mismatch 305 
(C/A, C in the probe) whereas RC2 is an intermediate (T/C, T in the probe), and RC3 an even less 306 
destabilising mismatch (T/G, T in the probe). The HTN3 and SEMG1 SNPs are located towards the 307 
probe termini and are therefore less destabilising. Although the Tm decreases recorded from the 308 
SNPs were greater than the Tm variation observed between donors in the previous testing, none of 309 
the shifted peak Tms corresponded to gDNA peaks seen in previous testing, and so they would not be 310 
confused with them when examining results from real samples. Due to a lack of population data 311 
associated with the reported SNPs we identified, it is not possible for us to determine the likelihood 312 
that these SNPs will be encountered if an expanded number of donors were to be tested. However, 313 
if further testing suggests they are likely to be seen, they can be offset by incorporation of universal 314 
bases if this is required. The use of universal bases is unlikely to prevent target detection. There was 315 
no statistically significant difference in the peak heights from any of the RC oligos compared to the 316 
wild type (t-test, p≥Ϭ.ϬϱͿ.  317 
 318 
Summary 319 
The data presented demonstrates the feasibility of a HyBeacons® approach to RT-PCR detection of 320 
mRNA using forensically relevant body fluids as a working example. The assays developed here have 321 
sufficient sensitivity and specificity to detect body fluid mRNA extracted from swabs and to 322 
differentiate between mRNA and gDNA through differences in melt peak Tm. Furthermore, this 323 
research has demonstrated the potential of combining RT-PCR and HyBeacon probes for detecting 324 
SNPs in expressed genes in the presence of gDNA, offering another molecular detection approach in 325 
health related studies.  326 
In their current form the assays could be slotted into existing forensic workflows to test extracted 327 
nucleic acid material containing both gDNA and mRNA. The use of HyBeacon probes also offers the 328 
possibility to multiplex reactions together and differentiate between targets using different dye 329 
labels. This work will form a large part of the future development of this approach. These assays 330 
were quick to design and offer a more rapid, sensitive and specific approach than many of the 331 
current body fluid detection methods in use.  However, it is important to note that some mRNA 332 
markers identified in the wider literature are also expressed at a low level in non-target tissues [14]. 333 
Traditional RT-qPCR approaches are able to use Cq values to distinguish between high expression of 334 
target mRNAs in target tissues versus lower expression in non-target tissues. However, primer 335 
design, cycling conditions and enzyme choice can also significantly impact the sensitivity of an assay 336 
to these lower-level expression profiles, and may account for some of the variation in reporting of 337 
specificity in the existing literature. Expanding the specificity testing of the assays developed here to 338 
non-target body fluids that may be encountered in routine forensic case work (such as urine, tears, 339 
nasal mucosa or sweat [41]) will be an essential part of any future validation work. Any unexpected 340 
results suggesting low-level expression of markers in non-target tissues will be investigated, and 341 
assay designs can be altered to prevent the detection of low-level expression if required. 342 
 343 
Acknowledgements 344 
The authors would like to thank Monika Panasiuk and Rebecca Horrell for their assistance in reagent 345 
preparation. They would also like to thank the body fluid donors, without whom this work would not 346 
have been possible. This material is based upon work supported by the U. S. Army Research Office 347 
and the Defense Forensic Science Center under contract number W911NF-14-C-0097.  The 348 
information contained within this report does not necessarily reflect the position or the policy of the 349 
Government, and no official endorsements should be inferred. The sponsor had no role in the study 350 
design; the collection, analysis or interpretation of data; the writing of the report; the decision to 351 
submit the article for publication. 352 
Conflicts of interest 353 
None. 354 
 355 
Author contributions 356 
All authors confirm that they have contributed to the intellectual content of this paper and have met 357 
the following 3 requirements: (a) critically important intellectual contribution to the conception, 358 
design and/or analysis and interpretation; (b) drafting the manuscript or critically reading it; and (c) 359 
through reading and final approval of the version to be published. 360 
 361 
References 362 
[1] D. French, C.L. Archard, T. Brown, D. McDowell. HyBeacon probes: a new tool for DNA sequence 363 
detection and allele discrimination. Mol Cell Probes 15 (2001) 363-374. 364 
 365 
[2] D. French, C.L. Archard, M. Andersen, D. McDowell. Ultra-rapid DNA analysis using HyBeacon 366 
probes and direct PCR amplification from saliva. Mol Cell Probes 16 (2002) 319-326. 367 
 368 
[3] D. French, N. Gale, T. Brown, D. McDowell, P. Debenham. HyBeacon probes for rapid DNA 369 
sequence detection and allele discrimination, Methods Mol. Biol. 429 (2008) 171-85. 370 
 371 
[4] S. Blackman, N. Dawnay, G. Ball, B. Stafford-Allen, N. Tribble, P. Rendell, K. Neary, E. Hanson, J. 372 
Ballantyne, B. Kallifatidis, J. Mendel, D.K. Mills, S. Wells. Developmental validation of the ParaDNA 373 
Intelligence System – a novel approach to DNA profiling, Forensic Science International: Genetics 17 374 
(2015) 137-48. 375 
 376 
[5] N. Dawnay, B. Stafford-Allen, D. Moore, S. Blackman, P. Rendell, E. Hanson, J. Ballantyne, B. 377 
Kallifatidis, J. Mendel, D.K. Mills, R. Nagy, S. Wells. Developmental validation of the ParaDNA 378 
Screening system – a presumptive test for the detection of DNA on forensic evidence items, Forensic 379 
Science International: Genetics, 11 (2014) 73-9. 380 
 381 
[6] N. Dawnay, R. Hughes, D. Syndercombe Court, N. Duxbury. Species detection using HyBeacon 382 
probe technology: working towards rapid onsite testing in non-human forensic and food 383 
authentification applications. Forensic Science International: Genetics 17 (2016) 103-11. 384 
 385 
[7] D. French, D. Jones, D. McDowell, J. Thompson, P. Debenham. Analysis of multiple single 386 
nucleotide polymorphisms closely positioned in the ovine PRNP gene using linear fluorescent probes 387 
and melting curve analysis, BMC Infectious Diseases 7:90 (2007). 388 
 389 
[8] N. Ben Gaied, J. Richardson, D. Singleton, Z. Zhao, D. French, T. Brown. End-capped HyBeacon 390 
probes for the analysis of human genetic polymorphisms related to warfarin metabolism, Organic & 391 
Biomolecular Chemistry 8 (2010) 2728-2734. 392 
 393 
[9] Dahan, L., Huang, L., Kedmi, R., Behlke, M.A. and Peer, D., 2013. SNP Detection in mRNA in Living 394 
Cells Using Allele Specific FRET Probes. PloS one, 8(9), p.e72389. 395 
 396 
[10] Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., 397 
Friedlander, R.M., Silani, V., Hayden, M.R. and Timmusk, T., 2001. Loss of huntingtin-mediated BDNF 398 
gene transcription in Huntington's disease. Science, 293(5529), pp.493-498. 399 
 400 
[11] Su, J., Heng, J., Huang, T., Peng, L., Yang, C. and Li, Q., 2012. Identification, mRNA expression and 401 
genomic structure of TLR22 and its association with GCRV susceptibility/resistance in grass carp 402 
(Ctenopharyngodon idella). Developmental & Comparative Immunology, 36(2), pp.450-462. 403 
 404 
[12] Fell, J.M., Paintin, M., Arnaud-Battandier, F., Beattie, R.M., Hollis, A., Kitching, P., Donnet-405 
Hughes, A., MacDonald, T.T. and Walker-Smith, J.A., 2000. Mucosal healing and a fall in mucosal pro-406 
inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. 407 
Alimentary Pharmacology and Therapeutics, 14(3), pp.281-290. 408 
 409 
[13] M. Bauer. RNA in forensic science, Forensic Science International: Genetics 1 (2007) 69–74. 410 
 411 
[14] T. Sijen. Molecular approaches for forensic cell type identification: On mRNA, miRNA, DNA 412 
methylation and microbial markers, Forensic Science International: Genetics 18 (2014) 21–32. 413 
 414 
[15] N. Watson. Chapter 15: Analysis of body fluids, in: P. C. White ed. Crime Scene to Court: The 415 
Essentials of Forensic Science 3rd Edition (2010) p438-467, RSC Publishing. 416 
 417 
[16] Abacus diagnostics Hematrace kits: http://www.abacusdiagnostics.com/hematrace.htm  418 
 419 
[17] N. Frascione, R. Thorogate, B. Daniel, S. Jickells. Detection and identification of body fluid stains 420 
using antibody-nanoparticle conjugates, Analyst 137 (2012) 508-12. 421 
 422 
[18] BA. Vidaki, B. Daniel, D. Syndercombe Court. Forensic DNA methylation profiling—Potential 423 
opportunities and challenges, Forensic Science International 7 (2013) 499–507. 424 
 425 
[19] Hwan Young Lee, Ja Hyun An, Sang-Eun Jung, Yu Na Oh, Eun Young Lee, Ajin Choi, Woo Ick Yang, 426 
Kyoung-Jin Shin. Genome-wide methylation profiling and a multiplex construction for the 427 
identification of body fluids using epigenetic markers, Forensic Science International: Genetics, 17 428 
(2015) 17–24. 429 
 430 
[20] Jong-Lyul Park, Oh-Hyung Kwon, Jong Hwan Kim, Hyang-Sook Yoo, Han-Chul Lee, Kwang-Man 431 
Woo, Seon-Young Kim, Seung-Hwan Lee, Yong Sung Kim. Identification of body fluid-specific DNA 432 
methylation markers for use in forensic science, Forensic Science International: Genetics 13 (2014) 433 
147–153. 434 
 435 
[21] Zheng Wang, Di Zhou, Yandong Cao, Zhen Hu, Suhua Zhang, Yingnan Bian, Yiping Hou, Chengtao 436 
Li. Characterization of microRNA expression profiles in blood and saliva using the Ion Personal 437 
Genome Machine® System (Ion PGM™ SysteŵͿ, ForeŶsiĐ SĐieŶĐe IŶterŶatioŶal: GeŶetiĐs ϮϬ ;ϮϬϭϲͿ 438 
140-146. 439 
 440 
[22] E.K. Hanson, J. Ballantyne. Identification of Forensically Relevant Body Fluids Using a Panel 441 
of Differentially Expressed microRNAs. Anal. Biochem.  387 (2009) 303-314. 442 
 443 
[23] Sarah S. Silva, Cátia Lopes, A.L. Teixeira, M.J Carneiro de Sousa, R. Medeiros. Forensic miRNA: 444 
Potential biomarker for body fluids? Forensic Science International: Genetics 14 (2014) 1–10. 445 
 446 
[24] J. Juusola, J. Ballantyne. Messenger RNA profiling: a prototype method to supplant conventional 447 
methods for body fluid identification, Forensic Science International 135 (2003) 85-96. 448 
 449 
[25] J. Juusola, J. Ballantyne. Multiplex mRNA profiling for the identification of body fluids, Forensic 450 
Science International 152 (2005) 1-12. 451 
 452 
[26] A. Kraus, D. Patzelt, M. Bauer. Detection of epithelial cells in dried blood stains by reverse 453 
transcriptase-polymerase chain reaction, J. Forensic Sci 44 (1999) 1232-1236. 454 
 455 
[27] M. Setzer, J. Juusola, J. Ballantyne. Recovery and stability of RNA in vaginal swabs and blood, 456 
semen and saliva stains, J. Forensic Sciences 53 (2008) 296-305. 457 
 458 
[28] Mara L. Lennard Richard, Kathryn A. Harper, Rhonda L. Craig, Anthony J. Onorato, James M. 459 
Robertson, Joseph Donfack. Evaluation of mRNA marker specificity for the identification of five 460 
human body fluids by capillary electrophoresis, Forensic Science International: Genetics 6 (2012) 461 
452-60. 462 
 463 
[29] P. Danaher, R. Lynn White, E. K. Hanson, J. Ballantyne. Facile semi-automated forensic body 464 
fluid identification by multiplex solution hybridization of NanoString® barcode probes to specific 465 
mRNA targets, Forensic Science International: Genetics 14 (2014) 18–30. 466 
 467 
[30] E.K. Hanson, J. Ballantyne, Highly specific mRNA biomarkers for the identification of vaginal 468 
secretions in sexual assault investigations, Sci. Justice 53 (2013) 14–22. 469 
 470 
[31] C. Haas, E. Hanson, W. Bär, R. Banemann, A.M. Bento, A. Berti, E. Borges, C. Bouakaze, A. 471 
Carracedo, M. Carvalho, A. Choma, M. Dötsch, M. Durianciková, P. Hoff-Olsen, C. Hohofn, P. 472 
Johansen, P.A. Lindenbergh, B. Loddenkötter, B. Ludes, O. Maroñas, N. Morling, H. Niederstätter, W. 473 
Parson, G. Patel, C. Popielarz, E. Salata, P.M. Schneider, T. Sijen, B. Sviezená, L. Zatkalíková, J. 474 
Ballantyne. mRNA profiling for the identification of blood – results of a collaborative EDNAP exercise, 475 
Forensic Science International: Genetics 5 (2011) 21-26.  476 
 477 
[32] C. Haas, E. Hanson, M.J. Anjos, W. Bär, R. Banemann, A. Berti, E. Borges, C. Bouakaze, A. 478 
Carracedo, M. Carvalho, V. Castella, A. Choma, G. De Cock, M. Dötsch, P. Hoff-Olsen, P. Johansen, F. 479 
Kohlmeier, P.A. Lindenbergh, B. Ludes, O. Maroñas, D. Moore, M.-L. Morerod, N. Morling, H. 480 
Niederstätter, F. Noel, W. Parson, G. Patel, C. Popielarz, E. Salata, P.M. Schneider, T. Sijen, B. 481 
SviežeŶa, M. TuraŶská, L. )atkalíkoǀá, J. BallaŶtyŶe. RNA/DNA Đo-analysis from blood stains – Results 482 
of a second collaborative EDNAP exercise. Forensic Science International: Genetics 6 (2012) 70-80. 483 
 484 
[33] C. Haas, E. Hanson, M.J. Anjos, R. Banemann, A. Berti, E. Borges, A. Carracedo, M. Carvalho, C. 485 
Courts, G. De Cock, M. Dötsch, S. Flynn, I. Gomes, C. Hollard, B. Hjort, P. Hoff-Olsen, K. Hríbiková, A. 486 
Lindenbergh, B. Ludes, O. Maroñas, N. McCallum, D. Moore, N. Morling, H. Niederstätter, F. Noel, W. 487 
Parson, C. Popielarz, C. Rapone, A.D. Roeder, Y. Ruiz, E. Sauer, P.M. Schneider, T. Sijen, D. 488 
SyŶderĐoŵďe Court, B. SǀiežeŶá, M. TuraŶská, A. Vidaki, L. )atkalíkoǀá, J. BallaŶtyŶe. RNA/DNA Đo-489 
analysis from human saliva and semen stains – Results of a third collaborative EDNAP exercise, 490 
Forensic Science International: Genetics 7 (2013) 230-239. 491 
 492 
[34] C. Haas, E. Hanson, M.J. Anjos, K.N. Ballantyne, R. Banemann, B. Bhoelai, E. Borges, M. Carvalho, 493 
C. Courts, G. De Cock, K. Drobnic, M. Dötsch, R. Fleming, C. Franchi, I. Gomes, G. Hadzic, S.A. 494 
Harbison, J. Harteveld, B. Hjort, C. Hollard, P. Hoff-Olsen, C. Hüls, C. Keyser, O. Maroñas, N. 495 
McCallum, D. Moore, N. Morling, H. Niederstätter, F. Noël, W. Parson, C. Phillips, C. Popielarz, A.D. 496 
Roeder, L. Salvaderi, E. Sauer, P.M. Schneider, G. Shanthan, D. Syndercombe Court, M. Turanská, 497 
R.A.H. van Oorschot, M. Vennemann, A. Vidaki, L. Zatkalíková, J. Ballantyne. RNA/DNA co-analysis 498 
from human menstrual blood and vaginal secretion stains: Results of a fourth and fifth collaborative 499 
EDNAP exercise. Forensic Science International: Genetics 8 (2014) 203-212. 500 
 501 
[35] C. Haas, E. Hanson, R. Banemann, A.M. Bento, A. Berti, Á. Carracedo, C. Courts, G. De Cock, K. 502 
Drobnic, R. Fleming, C. Franchi, I. Gomes, G. Hadzic, S.A. Harbison, B. Hjort, C. Hollard, P. Hoff-Olsen, 503 
C. Keyser, A. Kondili, O. Maroñas, N. McCallum, P. Miniati, N. Morling, H. Niederstätter, F. Noël, W. 504 
Parson, M.J. Porto, A.D. Roeder, E. Sauer, P.M. Schneider, G. Shanthan, T. Sijen, D. Syndercombe 505 
Court, M. Turanská, M. van den Berge, M. Vennemann, A. Vidaki, L. Zatkalíková, J. Ballantyne. 506 
RNA/DNA co-analysis from human skin and contact traces – results of a sixth collaborative EDNAP 507 
exercise, Forensic Science International: Genetics 16 (2015) 139-147. 508 
 509 
[36] R.F. Fleming, H.M.R. Baker, M.V. Fallow, P.M. Simon, J.K. Stacey, R.J. Wivell, S.A. Harbison. 510 
Impementation of messenger RNA body fluid testing in forensic case work. Conference proceedings 511 
oral presentations ISHI 22 (2011). 512 
https://www.promega.com/~/media/files/resources/conference%20proceedings/ishi%2022/oral%2513 
0presentations/fleming.pdf  514 
 515 
[37] BA. Lindenbergh, P. Maaskant, T. Sijen. Implementation of RNA profiling in forensic casework. 516 
Forensic Science International: Genetics, 7 (2013) 159-166. 517 
 518 
[38] E. Hanson, J. Ballantyne. Rapid and inexpensive body fluid identification by RNA profiling-based 519 
multiplex High Resolution Melt (HRM) analysis. F1000Research 2:218 (2013). 520 
 521 
[39] AmplifX 1.7.0 by Nicolas Jullien, CNRS, Aix-Marseille Université. Available at: http://crn2m.univ-522 
mrs.fr/pub/amplifx-dist. Accessed on  18 May 2015. 523 
 524 
[40] Primer BLAST – A tool for finding specific primers. Available at: 525 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome. Accessed on 3rd 526 
June 2015. 527 
 528 
[41] M. van den Berge, B. Bhoelai, J. Harteveld, A. Matai, T. Sijen. Advancing forensic RNA typing: On 529 
non-target secretions, a nasal mucosa marker, a differential co-extraction protocol and the 530 
sensitivity of DNA and RNA profiling. Forensic Science International: Genetics 20 (2016) 119-129. 531 
 532 
Figure 1: Diagram showing different HyBeacon approaches for DNA identification A) SNP detection as used in medical and food authentication applications, 533 
B) STR detection with the use of a blocker oligo, and C) the proposed approach for detection and differentiation of gDNA and mRNA. 534 
535 
Table 1: Selected mRNA markers, primers and HyBeacon probe designs. 536 
537 
mRNA marker
Target 
body fluid
GenBank
Accession 
number Oligo name Sequence
ALAS2
5’-aminolevulinate 
synthase 2
Peripheral
blood
NM_001037967.3 ALAS2 Fwd primer GGCATGAGCCGACACCCTCAG
ALAS2 Rev primer CCTGAGATGTTGCGGGTGCCAC
ALAS2 probe CTGCAGGG-T(FAM)-CTCCTG-T(FAM)-GTGG-cap
CYP2B7P1
Cytochrome P450, 
family 2, subfamily 
B, member 7, 
pseudogene
CVF NR_001278.1 CYP2B7P1 Fwd 
primer
CAAATCCTTTCTGAGGTTCCGAGA
CYP2B7P1 Rev 
primer
GGTTTCCATTGGCAAAGAGCAT
CYP2B7P1 probe GCATGCCATA-T(FAM)-CCCTGG-T(FAM)-AGACT-cap
HTN3
Histatin 3
Saliva NM_000200.2 HTN2 Fwd primer TGGAGCTGATTCACATGCAAAGAGACAT
HTN3 Rev primer GCGAATTTGCCAGTCAAACCTCCATAATC
HTN3 probe GATG-T(FAM)-GAATGA-T(FAM)-GCTTTTCATGGA-cap
MMP10
Matrix 
metalloproteinase 
stromelysin-2
Menstrual
blood
X07820.1 MMP10 Fwd primer GTCACTTCAGCTCCTTTCCTGGCA
MMP10 Rev primer CTGTGTCCTGGGCCATCAA
MMP10 probe TTACATACAGGATTG-T(FAM)-GAATTA-T(FAM)-ACACCAG-cap
SEMG1
Semenogelin I
Seminal fluid NM_003007.3 SEMG1 Fwd primer CCAACATGGATCTCATGGGGGATTG
SEMG1 Rev primer AGCATGGGCAGGTGGTGTCAT
SEMG1 probe ACCAATATCAAGG-T(FAM)-GTCAGT-T(FAM)-GACC-cap
 538 
Figure 2: Results from HyBeacon assays run with either target body fluid mRNA, purified gDNA or 539 
NTC. Results shown are the mean of 3 repeats for each input type. Target body fluid mRNA was 540 
peripheral blood (ALAS2, image a), vaginal fluid (CYP2B7P1, image b), saliva (HTN3, image c), 541 
menstrual blood (MMP10, image d) or seminal fluid (SEMG1, image e). 542 
 543 
 544 
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 546 
Figure 3: Specificity of ALAS2 (blood marker) and CYP2B7P1 (vaginal marker) to target mRNA. 547 
Template mRNA inputs are coloured as follows: red – peripheral blood, purple – menstrual blood, 548 
green – vaginal secretions, blue – saliva, orange – seminal fluid.  Cq values for the different template 549 
inputs varied: ALAS2 peripheral blood (red trace, mean Cq 32.37, s.d. 0.07), menstrual blood (purple 550 
trace, mean Cq 31.3, s.d. 0.14), CYP2B7P1 vaginal (green trace, mean Cq 37.47, s.d. 0.53), menstrual 551 
blood (purple trace, mean Cq 30.47, s.d. 0.25). Means are calculated from 3 repeats of the same 552 
extract. 553 
 554 
Table 2: Mean peak Tms and Cq values achieved from target body fluid extracts from multiple donors 555 
and mean peaks from gDNA input. Italicised numbers in brackets below mean Tms indicate standard 556 
deviations. * indicates that one of the donors included is represented only by a menstrual swab 557 
rather than a target body fluid swab. Donor swab extractions run in duplicate. Estimated number of 558 
copies of target mRNA species in 1ng total RNA extracted from swabs estimated based on 559 
comparison of Cq values with plasmid dilutions. Total RNA will include any microbial RNA extracted 560 
from the swab – this will represent a considerable contribution in body fluids such as saliva, 561 
cervicovaginal fluid and menstrual blood. As indicated in Figure 2, no gDNA peak is produced in the 562 
saliva (HTN3) assay. 563 
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 565 
Table 3: SNPs identified within markers of interest from both GenBank data analysis and sequencing 566 
of individuals from diverse populations. Where multiple SNP variants have been identified at the 567 
same location the number of SNP sites is given, in addition to the total number of SNP variants 568 
identified (HTN3 only). More information on the location of the SNPs within the probe sequences is in 569 
Table 4.  570 
 571 
 572 
 573 
Table 4: Reverse complement oligonucleotides for testing of known SNPs at probe sites. Underlined 574 
sections in the wild type RCs indicate base situated opposite a fluorophore once the probe is bound. 575 
Bold bases in the RC sequence indicate SNPs. Mean melt peak Tm calculated from six replicates. 576 
mRNA target Number of 
donors 
tested
Mean 
target peak 
Tm ( C)
Mean Cq
from mRNA 
target
Mean gDNA
peak Tm ( C)
Estimated # 
copies/1ng 
total RNA
ALAS2
Peripheral blood
9* 57.4
(0.3)
30.8
(1.3)
44.5
(0.5)
7409.0
CYP2B7P1
CVF
6* 58.8
(0.3)
33.2
(3.4)
49.0
(0)
12.3
HTN3
Saliva
5 55.7
(0.8)
33.0
(1.7)
n/a 16763.2
MMP10
Menstrual blood
4 57.3
(0.3)
33.5
(2.0)
54.1
(0.29)
178.5
SEMG1
Seminal fluid
7 59.1
(0.5)
28.9
(1.7)
45.8
(0.58)
1251.6
mRNA marker Target fluid
Genomic 
location
Exonic amplicon 
length
Total number of SNPs 
identified within amplicon
SNPs occurring 
within probe sites
ALAS2 Blood Xp11.21 92 2 0
MMP10 Menstrual blood 11q22.3 226 27 0
HTN3 Saliva 4q13 158 19 3 (2 loci)
SEMG1 Semen 20q12-q13.2 255 23 1
CYP2B7P1 Vaginal fluid 19q13.2 203 14 3
Where multiple SNP variants have been identified at the same location the number of SNP sites is given in addition to the 
 577 
 578 
Oligo Name Sequence Mean melt peak Tm
( C)
CYP2B7P1 Wild Type 5’ AGTCTACCAGGGATATGGCATGC 3’ 66.48
CYP2B7P1 RC1 5’ ----------A------------ 3’ 59.44
CYP2B7P1 RC2 5’ ------------C---------- 3’ 61.68
CYP2B7P1 RC3 5’ -------------------G--- 3’ 64.10
HTN3 Wild Type 5’ TCCATGAAAAGCATCATTCACATC 3’ 61.56
HTN3 RC1 5’ –T---------------------- 3’ 59.29
HTN3 RC2 5’ -----------------------A 3’ 60.55
HTN3 RC3 5’ -----------------------T 3’ 60.65
SEMG1 Wild Type 5’ GGTCAACTGACACCTTGATATTGGT 3’ 64.78
SEMG1 RC1 5’ -----------------------A- 3’ 62.20
